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Abstract Ahnak1 is a giant, ubiquitously expressed,
plasma membrane support protein whose function in skel-
etal muscle is largely unknown. Therefore, we investigated
whether ahnak would be inﬂuenced by alterations of the
sarcolemma exempliﬁed by dysferlin mutations known to
render the sarcolemma vulnerable or by mutations in cal-
pain3, a protease known to cleave ahnak. Human muscle
biopsy specimens obtained from patients with limb girdle
muscular dystrophy (LGMD) caused by mutations in dys-
ferlin (LGMD2B) and calpain3 (LGMD2A) were investi-
gated for ahnak expression and localization. We found that
ahnak1 has lost its sarcolemmal localization in LGMD2B
but not in LGMD2A. Instead ahnak1 appeared in muscle
connective tissue surrounding the extracellular site of the
muscle ﬁber in both muscular dystrophies. The entire giant
ahnak1 molecule was present outside the muscle ﬁber and
did only partially colocalize with CD45-positive immune
cell inﬁltration and the extracelluar matrix proteins ﬁbro-
nectinandcollagenVI.Further,vesiclessheddedinresponse
to Ca
2? by primary human myotubes were puriﬁed and their
protein content was analysed. Ahnak1 was prominently
present in these vesicles. Electron microscopy revealed a
homogenous population of vesicles with a diameter of about
150 nm. This is the ﬁrst study demonstrating vesicle release
from human myotubes that may be one mechanism under-
lying abnormally localized ahnak1. Taken together, our
results deﬁne ahnak1 in muscle connective tissue as a novel
feature of two genetically distinct muscular dystrophies that
might contribute to disease pathology.
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Introduction
Proper skeletal muscle function relies on muscle ﬁber
integrity, efﬁcient muscle repair and regeneration which are
disturbed in muscular dystrophies (Goldstein and McNally
2010).Limbgirdlemusculardystrophies (LGMD) comprise
clinically and genetically heterogenous disorders charac-
terized by progressive wasting of the skeletal muscle com-
bined with an increase in muscle connective tissue. LGMD
type 2B and LGMD type 2A are caused by mutations in
dysferlin (MIM*603009) and calpain3 (MIM*114240),
respectively (Bashir et al. 1998; Richard et al. 1995). Dys-
ferlin is a sarcolemmal protein involved in plasma mem-
brane repair and muscle regeneration (Bansal et al. 2003;
Chiu et al. 2009). Mutations in dysferlin lead to reduced
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protein in muscle ﬁbers (Wenzel et al. 2006; Spuler et al.
2008; Krahn et al. 2009). Calpain3 is a cystein protease that
cleaves cytoskeletal and myoﬁbrillar proteins and is repor-
ted to serve as gatekeeper of proper sarcomere function
(Kramerova et al. 2005; Beckmann and Spencer 2008).
Ahnak1 (desmoyokin, MIM*103390) interacts with
dysferlin and is cleaved by calpain 3 (Huang et al. 2007,
2008). Ahnak1 is a large protein implicated in plasma
membrane support (Hohaus et al. 2002; Gentil et al. 2003)
and Ca
2? signaling in a variety of cells (Hashimoto et al.
1995; Haase 2007; Matza et al. 2008; Alli and Gower 2009;
Alvarez et al. 2010). Much attention has been paid to ahnak
as a marker of enlargeosomes, which are non-secretory,
cytoplasmic vesicles competent for regulated exocytosis
after rising intracellular Ca
2?. Enlargeosomes mediate cell
surface enlargement and contribute to plasma membrane
repair and vesicle shedding (Borgonovo et al. 2002; Coc-
ucci et al. 2007; Lorusso et al. 2006). Little is known about
ahnak function in skeletal muscle. Recently, ahnak1 and
ahnak2 have been described as costameric proteins (Marg
et al. 2010). Furthermore, ahnak has been identiﬁed as a
constituent of the dysferlin protein complex that is
important for sarcolemmal integrity (Huang et al. 2007,
2008; de Morree et al. 2010). Interestingly, the interaction
between ahnak1 and dysferlin is lost after proteolytic
processing of ahnak1 by calpain3 (Huang et al. 2008).
Because of the complex interactions between ahnak1,
dysferlin, and calpain3 and their role in muscle repair and
regeneration we compared ahnak1 expression in patients
with LGMD2B and LGMD2A. We found an altered
expression of ahnak1 at the sarcolemma and identiﬁed
ahnak1 as a novel constituent of the endomysial compart-
ment in the two genetically distinct muscular dystrophies
studied. Furthermore, we demonstrate the release of ah-
nak1-containing vesicles from normal human myotubes
after rising intracellular Ca
2?. We infer that ahnak1 release
by secreted vesicles may be one mechanism underlying
abnormally localized ahnak1 in muscular dystrophy.
Materials and methods
Patients
The Charite ´ internal review board approved the study and
written informed consent was obtained from all patients.
Skeletalmusclebiopsies(M.vastuslateralis)from6patients
with dysferlinopathy, 6 patients with calpainopathy and 6
healthy controls were analyzed. Patients with LGMD2B
were affected by different mutations in DYSF including
homozygous c.4022T[C; homozygous c.2810 ? 2T[
A; compound heterozygous c.855 ? 1delG and
c.895G[A; compound heterozygous c.1448C[A and
c.*107T[A; compound heterozygous c.5606G[A and
c.2875C[T (see Table 2 in (Wenzel et al. 2006)) resulting
in the complete loss or intracellular accumulation of dys-
ferlin, respectively. Patients with LGMD2A were affected
by different compound heterozygous mutations in the cal-
pain3 gene including c.550delA and c.1745 ? 5G[C;
c.550delA and c.883_886delGATAinsCTT; c.1469G[A
and c.1801-1G[A; c.700G[A and c.1324T[C;
c.551C[T and c.801 ? 1G resulting in the complete loss
or reduced expression of calpain3, respectively.
Antibodies against ahnak
The isoform-speciﬁc ahnak1 antibody was prepared by
immunizing rabbits with a C-terminal recombinant ahnak1
protein fragment (amino acid residues 4893-5535) as
recently described (Marg et al. 2010). In some experiments
ahnak was labeled with the KIS antibody that was raised
against the internal repeating units of ahnak (KIS-
MPDVDLHLKGPK). The KIS antibody has been charac-
terized elsewhere (Haase et al. 2004) and corresponds to
the antibody used by Huang et al. (2007, 2008). The
monoclonal antibody (M01, clone 3G7) against the N-ter-
minal part of ahnak1 was purchased from Abnova.
SDS-PAGE and Western blot analysis
Total protein fractions were extracted from frozen tissue
specimens and myotubes by homogenization with SDS-
sample buffer as previously described (Haase et al. 2004).
Exosomal proteinswere dissolvedinSDS-sample bufferand
heated at 95C for 5 min. Protein samples were separated by
SDS-PAGEandtransferredtonitrocelluloseﬁltersovernight
at 70 mA with a Tris/glycine buffer, pH 8.3, containing 10%
methanol and 0.1% SDS in a Biorad Protean III system. The
transferred proteins were visualized by staining with Pon-
ceau-S. Membranes were further processed for immunode-
tection according to standard protocols. Brieﬂy, they were
subsequently incubated with the afﬁnity-puriﬁed, polyclonal
antibody against ahnak1 (1 lg IgG/ml) or monoclonal anti-
bodies against desmin (DAKO) and annexin2 (BD Labora-
tories) for 90 min and the respective secondary horseradish
peroxidase-conjugated antibodies (Pierce, Rockford, USA).
Immunoreactive protein bands were visualized by Chemi-
luminescentHRPSubstrate(Millipore,USA)andAmersham
Hyperﬁlm (GE Healthcare, Japan).
Myoblast puriﬁcation and differentiation
Biopsies were taken from M.vastus lateralis. Primary
myoblast cultures were isolated by protease digestion from
fresh muscle biopsies and expanded at 37C in humidiﬁed
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123atmosphere with 5% CO2 in skeletal muscle growth med-
ium (PromoCell, Heidelberg, Germany) supplemented with
10% FCS, glutamine (3 mM) and gentamycin (40 lg/ml)
(Gibco, Paisely, UK). All cultures were enriched in myo-
blasts by immuno-magnetic cell sorting using anti-CD56/
NCAM antibody coated magnetic beads (Miltenyi Biotech,
Bergisch Gladbach, Germany). Purity of the myoblast
preparation was veriﬁed by staining with an anti-desmin
antibody (DAKO) revealing more than 95% desmin-posi-
tive cells. Differentiation of myoblasts into myotubes was
initiated at approximately 90% conﬂuence by switching to
differentiation medium (DMEM, 2% horse serum) fol-
lowed by cultivation for 7 days.
Immunocytochemistry
Myoblasts were grown in 8 well chamber slides (Nunc,
Langenselbold, Germany) and differentiated into myotu-
bes, ﬁxed for 10 min with 4% formaldehyde, permeabili-
zed for 15 min with 0.2%Triton X100 and blocked with
1% BSA diluted in PBS. The following primary antibodies
were used for immunostaining: mouse monoclonal anti-
bodies to MyHCs (Novocastra, Newcastle upon Tyne, UK),
dystrophin (Abcam), a-actinin and vinculin (both from
Sigma-Aldrich) and rabbit polyclonal antibodies to human
ahnak1 (3 lg IgG/ml) in combination with secondary
Alexa 488-conjugated anti-mouse IgG or Alexa 594-con-
jugated anti-rabbit IgG antibodies (Invitrogen), respec-
tively. Nuclei were counterstained with Hoechst 33258.
Images were collected with a Leica DMI6000 ﬂuorescence
microscope.
Immunohistochemistry
Immunoﬂuorescenct staining was performed on transversal
5 lm cryostat sections of skeletal muscle biopsies
(M.vastus lateralis) of patients with dysferlinopathy, cal-
painopathy and healthy controls. After ﬁxation with aceton,
muscle sections were blocked with 10% goat serum in PBS
and stained with rabbit polyclonal anti-ahnak1, anti-ﬁbro-
nectin (Abcam) or KIS antibodies in combination with
Alexa 594-conjugated anti-rabbit IgG antibodies (Invitro-
gen). Sections were double-labelled with a monoclonal
antibody to dystrophin C-terminus (Novocastra), CD45
(BD Laboratories) or ahnak1-NT (Abnova) in combination
with Alexa 488-conjugated anti-mouse IgG antibodies
(Invitrogen) to highlight the sarcolemma. Negative control
samples without primary or secondary antibodies were
included and produced negligible ﬂuorescence. Images
were collected with a Leica DM6000 or BioRad MRC1024
microscope. To block speciﬁc interactions, rabbit poly-
clonal anti-ahnak1 antibody was preincubated with a
20-fold molar excess of the recombinant ahnak1-GST
fusion protein used for immunization (see Antibodies)
overnight at 4C and applied to cryosections as described
above. For semiquantitative analysis ahnak1 localization
was grouped into four categories after visual inspection of
sections from patients with calpainopathy, dysferlinopathy
and healthy controls: absent, partially reduced or present at
the sarcolemma and localized to the endomysium.
Vesicle puriﬁcation and characterization
Secretedvesicleswereisolatedbydifferentialcentrifugation
from cell culture supernatants of human myotubes differ-
entiated in 10 cm diameter petri dishes. After 24 h in serum
free media the myotubes were washed with fresh medium
and then exposed, for 10 min at room temperature, to ion-
omycin (1 lM, 3.7 lM), phorbol(12-myristoyl-13-acetyl)
(0.5 lM), and ATP (1 mM) or to their solvents, diluted in
2 ml medium. At the end of the incubations, the media were
harvested and subjected to differential centrifugation at 4C
starting with 4.0009g to remove large cell remnants. The
resulting supernatants were ﬁltered through a syringe ﬁlter
with 0.22 lm cut-off (Millipore), and the ﬁltrates were
centrifuged at 100.0009g in an Optima ultracentrifuge
(Beckman-Coulter) for 2 h to pellet vesicles which were
only visible upon ionomycin treatment. The pellets
(*50 lg of protein/petri dish) were either resuspended for
Westernblottingorwereprocessedfornegativestainingand
electron microscopy. For the latter method, the preparations
were ﬁxed in 2% freshly prepared formaldehyde in 200 mM
HEPES buffer, pH 7.4 over night. Small aliquots of this
mixture were applied to formvar-carbon-coated grids for
5 min, washed shortly with bidistilled water and stained
with 5% aqueous uranyl acetate. Images were taken with a
Zeiss 910 electron microscope equipped with a 1 k 9 1k
high speed slow scan CCD camera and the iTEM software
(Olympus Soft Imaging Solutions, Mu ¨nster, Germany).
Results
Ahnak1 is mislocalized in dysferlinopathy
and calpainopathy
To examine potential alterations in the distribution of ah-
nak1 in muscular dystrophies caused by mutations in
dysferlin and calpain3, we employed a recently character-
ized ahnak1 isoform-speciﬁc antibody (Marg et al. 2010).
Cross sections of normal human skeletal muscle revealed a
sarcolemma associated staining pattern for ahnak1 (Fig. 1,
upper panel, green) that closely merged with dystrophin
labeling (Fig. 1, upper panel, red). Next we analyzed the
distribution of ahnak1 in patients with dysferlinopathy and
calpainopathy. In muscle from a LGMD2B patient, plasma
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123membrane staining with antibodies to dystrophin revealed
myopathic changes typical for dystrophic muscle, such as
pathological variations in ﬁber size, split ﬁbers, and an
increase in endomysial ﬁbrosis (Fig. 1, middle panel, red).
Ahnak1 labeling at the sarcolemma was dramatically
reduced in all six patients with dysferlinopathy, compared
to normal skeletal muscle. We show a representative
example in Fig. 1 (middle panel, green). Remarkably, we
observed strong immunostaining for ahnak1 outside the
muscle ﬁbers in the endomysium and perimysium in dys-
ferlinopathy (arrows in Fig. 1, middle panel). Sections of
skeletal muscle from patients with calpainopathy demon-
strated strong dystrophic changes including increased
endomysial ﬁbrosis, as revealed by sarcolemmal membrane
staining for dystrophin (Fig. 1, lower panel, red). In all six
patients with calpain3 mutations, ahnak1 was unchanged or
only slightly reduced at the sarcolemma (Fig. 1, lower
panel, green). Interestingly, merged images revealed strong
ahnak1 labeling outside the muscle ﬁber within the endo-
mysium in calpainopathy (arrows in Fig. 1, lower panel)
very similar to dysferlin-deﬁcient muscle as described
above. Thus, in both these dystrophies, ahnak1 was present
outside the muscle ﬁber in the endomysium and formed
line structures partially ensheathing the muscle ﬁber
(arrows in Fig. 1, middle and lower panel). Ahnak1
localization in patients and healthy controls is summarized
in Online Resource 1. The speciﬁcity of ahnak1 immuno-
staining in normal and dystrophic muscle was veriﬁed by
blocking ahnak1 labeling with the recombinant ahnak1
protein used to generate the antibody (Online Resource 2a).
We next addressed the question whether ahnak1 frag-
ments or the full-length protein reside outside the muscle
ﬁber in the endomysial compartment. Double labeling of
ahnak1 with antibodies directed against either the
Fig. 1 Endomysial ahnak1 deposits surrounding the sarcolemma in
dysferlinopathy and calpainopathy. Cross-sections of human skeletal
muscle were stained for ahnak1 together with dystrophin that
highlights the sarcolemma. Confocal microscopy of normal human
skeletal muscle demonstrated sarcolemmal localization of ahnak1
(green), together with dystrophin (red; upper panel). Skeletal muscle
from an exemplary patient with dysferlinopathy (middle panel) and an
exemplary patient with calpainopathy (lower panel) revealed strong
dystrophic changes combined with increased endomysial localization
of ahnak1. Ahnak1 formed line structures outside the muscle ﬁbers,
often parallel to the plasma membrane (arrows; bar,2 5lm)
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revealed perfect colocalization for both ahnak1 epitopes in
calpain3-deﬁcient muscle (Fig. 2a) and dysferlin-deﬁcient
muscle (data not shown). Western blots of tissue homoge-
nates from normal and dystrophic human skeletal muscle
revealed a single immunoreactive band for ahnak1 with the
expected high molecular mass (Fig. 2b). These ﬁndings
suggestthattheentiregiantahnak1moleculeispresentinthe
enlargedendomysiuminbothformsofmusculardystrophies.
Furthermore, we used the KIS antibody for ahnak label-
ing in muscle sections. This antibody was generated against
the repeating units of ahnak1 and is expected to detect both
ahnak1 and ahnak2. We observed strong, endomysial ah-
nak1/2 labeling in dysferlin-deﬁcient and calpain3-deﬁcient
patients (Online Resource 2b) that is consistent with a
localization of ahnak outside the muscle ﬁber as shown
above with the ahnak1 isoform-speciﬁc antibody.
Extracellular ahnak1 in relation to immune inﬁltration
and interstitial ﬁbrosis
To shed light on the origin of endomysial ahnak1, we
considered the possibility that ahnak1 was derived from
cells invading the endomysial space such as activated
macrophages and lymphocytes, in which ahnak1 expres-
sion is well documented (Matza et al. 2008; Matza and
Flavell 2009). We thus combined ahnak1 labeling with
staining for CD45, a marker for immune cells (Fig. 3). In
healthy human skeletal muscle, inﬁltration of immune cells
was hardly visible. Only a single rounded cell was detected
outside the skeletal muscle ﬁber that was labeled for both
CD45 and ahnak1 (Fig. 3, upper panel). Dystrophic muscle
from dysferlin-deﬁcient and calpain3-deﬁcient patients
revealed signiﬁcant CD45-positive immune cell inﬁltration
that partially co-localized with ahnak1 labeling. However,
ahnak1 showed a broader distribution and ahnak1-positive
line structures ensheathing the muscle ﬁbers were not
labeled by CD45 (Fig. 3, middle and lower panel). Thus,
inﬁltration of immune cells was probably not the only
reason for the presence of ahnak1 in the endomysium.
To relate ahnak1 expression to interstitial ﬁbrosis in
dystrophic muscle, we compared its localization with
ﬁbrosis markers, namely the extracellular matrix (ECM)
proteins ﬁbronectin and collagen VI (Alvarez et al. 2002;
Fadic et al. 2006). In healthy specimen, ﬁbronectin was only
slightly expressed and was preferentially localized at blood
vessels between muscle ﬁbers and in the perimysial space
(Fig. 4, upper panel). The increase in ﬁbrosis in dystrophic
muscle was accompanied by an increase in ﬁbronectin
expression in the endomysium in both dysferlinopathy and
calpainopathy (Fig. 4, middle and lower panel, respec-
tively). However, ﬁbronectin and ahnak1 showed only a
partially overlapping expression pattern in the endomysium
in dystrophic muscle. Fibronectin distribution was broader
and again the characteristic ahnak1-positive structures
embracing the sarcolemma were not highlighted by ﬁbro-
nectin (Fig. 4, middle and lower panel). Moreover, in dys-
trophic muscle ahnak1 showed a localization distinct from
the ECM molecule, collagen VI, and the basal lamina
marker, laminin a2 (Fig. 5). These ﬁndings support the
presence of ahnak1 outside the muscle ﬁber in dystrophic
muscle. However, ahnak1 does not entirely co-localize with
the ECM proteins ﬁbronectin, collagen VI, and laminin a2.
May extracellular ahnak1 originate from muscle?
We tested the hypothesis whether ahnak outside the muscle
ﬁber may be released from muscle through secreted vesi-
cles. We employed primary human myotubes as a model
and adapted protocols for vesicle shedding (Cocucci et al.
2007; Lorusso et al. 2006). Multinucleated myotubes were
formed from normal primary human myoblasts after 7 days
Fig. 2 Ahnak1 expression analyzed with domain-speciﬁc antibodies
in dystrophic muscle. a Ahnak1 labeling in a calpainopathy patient
with anti ahnak1-NT mAb and anti ahnak1 pAb directed against the
N-terminal and C-terminal region of ahnak1, respectively. There was
a strong co-localization of the N-terminal and C-terminal parts of
ahnak1 (bar,5 0lm). b Western blots from a healthy control (lane 1)
and from a patient with calpainopathy (lane 2) showed ahnak1
migrating as a single *700 kDa protein in both samples. Protein
staining of MyHC was used as loading control
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showed a striated staining pattern for myosin heavy chain
(MyHC) and a-actinin (labels Z-lines) indicative for the
formation of sarcomeres (Fig. 6). Costamere-like structures
were not yet developed. The costameric proteins vinculin
and dystrophin showed a focal adhesion-like staining
Fig. 3 Ahnak1 expression and inﬁltration of immune cells in
dystrophic human skeletal muscle. Cross-sections of normal human
skeletal muscle (upper panel), a patient with dysferlinopathy (middle
panel) and a patient with calpainopathy (lower panel) were labeled
for ahnak1 (green) and CD45 (red) as an immune cell marker (bar,
50 lm)
Fig. 4 Comparison of ahnak1
and ﬁbronectin expression in
normal and dystrophic human
skeletal muscle. Cross-sections
of normal human skeletal
muscle (upper panel), an
exemplary patient with
dysferlinopathy (middle panel),
and a patient with calpainopathy
(lower panel) were labeled for
ahnak1 (anti ahnak1-NT mAb;
green) and ﬁbronectin (red)a sa
marker for endomysial ﬁbrosis
(bar,5 0lm)
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123pattern and an intracellular localization, respectively
(Fig. 6). In myotubes ahnak1 was distributed throughout
the cytoplasm and at the plasma membrane (Fig. 6). Ah-
nak1 staining was only observed after permeabilization of
cells indicating that ahnak1 is not exposed at the outer
surface of the plasma membrane (data not shown).
To evoke vesicle shedding we incubated cultured
adherent myotubes with PMA, ionomycin, ATP or vehicle
as control. Media were harvested after 10 min of drug
application and were subjected to differential centrifuga-
tion as outlined in Materials and methods. The high speed
pellet following 100.0009g centrifugation was considered
as secreted vesicles and their protein composition was ana-
lysed by Western blotting. Figure 7a clearly demonstrates
that this fraction contained ahnak1 together with annexin 2
upon treatment with the Ca
2? ionophore ionomycin,
whereas the intermediate ﬁlament protein desmin was
absent. Robust release of ahnak1 into the vesicular fraction
was repeatedly seen at a concentration of 1 lM ionomycin,
while PMA (0.5 lM, Fig. 7a) and ATP (1 lM, data not
shown) failed to induce the release of any constituent into
the high speed pellet. Electron microscopy was performed
to characterize the vesicular fraction released by ionomycin
treatment. Representative images depicted in Fig. 7b
revealed that this myotube-derived preparation contained
rounded vesicles with a diameter of 150–200 nm. The
characteristics of repeated vesicle preparations are given in
Table 1. It is noteworthy to mention that an additional
Fig. 5 Comparison of collagen VI, laminin a2 and ahnak1 expression
in dystrophic human skeletal muscle. Cross-sections of human
skeletal muscle of an exemplary patient with calpainopathy (a) and
a patient with dysferlinopathy (b) were labeled for ahnak1 (red) and
collagen VI or laminin a 2( green), as a marker for endomysial
ﬁbrosis and basal lamina, respectively (bar,5 0lm)
Fig. 6 Differentiation state of primary human myotubes. Immuno-
ﬂuorescence staining with either anti-MyHC or with anti-a actinin
antibody showed correct organization of the sarcomere. Costamere-
like structures were not yet developed, as shown by staining with anti-
vinculin or anti-dystrophin antibody. Ahnak1 was distributed
throughout the cytoplasm and at the plasma membrane (bar,2 0lm)
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123puriﬁcation step through a 0.22 lm ﬁlter did essentially not
alter the dimensions of secreted vesicles. Importantly, no
evidence of contamination with other membrane particles
or cell remnants was observed in our vesicle preparation
(Fig. 7b).
Discussion
The important ﬁnding in our study is the localization of
ahnak1 outside the muscle ﬁber in patients with calpain-
opathy (LGMD2A) and dysferlinopathy (LGMD2B). We
believe this information implies that ahnak1 is faultily
regulated in the muscular dystrophies we investigated.
Elucidation of the mechanisms involved in ahnak1 mislo-
calization could help explain these muscle diseases further.
Healthy human skeletal muscle did not show endomysial
ahnak1. In cross sections, we observed a densely packed,
plasma membrane associated staining pattern for ahnak1
that closely merged with dystrophin labeling. Plasma
membrane localization is in line with previous reports and
supports the functional role of ahnak in skeletal muscle as a
plasma membrane stabilizer and costamer-associated pro-
tein (Hohaus et al. 2002; Haase et al. 2004; Gentil et al.
2003; Benaud et al. 2004; Marg et al. 2010). Speciﬁcally, in
patients with LGMD2B a separation between dystrophin
and ahnak1 became apparent as ahnak1 labeling at the
muscle membrane was strongly reduced. This ﬁnding is in
agreement with Huang et al. (2007) who described a con-
certed loss of dysferlin and ahnak at the plasma membrane
in dysferlinopathy patients. Loss of ahnak from the sarco-
lemma seems to be characteristic for dysferlinopathies
because it is not observed in calpainopathies. However,
endomysial localization of ahnak1 appeared to be a com-
mon feature in both muscle diseases. In fact, we found
ahnak1 accumulation in the enlarged interstitial compart-
ment of dysferlin-deﬁcient and calpain3-deﬁcient muscle.
Again, co-immunostaining of ahnak1 and dystrophin
allowed clear differentiation between plasma membrane
labeling and endomysial labeling. Ahnak1 staining alone
could have been misinterpreted as sarcolemmal thickening
or multilayered basal lamina. Several antibodies against
different domains of ahnak1 including N- and C-terminus as
well as the repeating units support ahnak1 deposition out-
side the dystrophic muscle ﬁber. Furthermore, we corrob-
orated the localization of ahnak1 outside the muscle ﬁbers
in the two diseases by partial co-labeling with the extra-
cellular matrix molecules ﬁbronectin and collagen VI.
These proteins are accepted constituents of endomysial
connective tissue in the dystrophic muscle.
In general, muscular dystrophies are characterized by a
progressive muscle weakness and wasting, in combination
with ﬁbrosis that contributes to disease severity (Alvarez
et al. 2002; Fadic et al. 2006; Goldstein and McNally
2010). Excessive accumulation of matrix components in
the endomysium may have strong effects on the activation
and differentiation of resident cells, and therefore muscle
regeneration. Skeletal muscle ﬁbers rely on a proper con-
nection with matrix to transduce muscle tension and to
maintain cell integrity. Endomysial deposition of ahnak1
could inﬂuence these processes. A barrier function for
ahnak expressing cells has been described after spinal cord
injury and at the blood brain barrier (Salim et al. 2009;
Gentil et al. 2005; von Boxberg et al. 2006). A similar
effect might be mediated by the ahnak1 positive line
structures partially ensheathing dystrophic muscle ﬁbers.
Therefore we suggest that ahnak1 deposition outside the
Fig. 7 Ahnak1 and annexin2 are present in vesicles secreted from
human myotubes. a Myotubes were incubated with 0.5 lM PMA,
1 lM ionomycin (Iono), or vehicle as control (Con) for 10 min.
Ahnak1 and annexin2 are present in vesicles secreted by ionomycin
treatment (left panel). The corresponding myotubes express ahnak1,
annexin2 and desmin (right panel) as assessed by Western blotting.
b Electron micrographs of secreted vesicles puriﬁed from ionomycin
treated myotubes. Representative images show rounded vesicles of
150–200 nm in diameter (bar, 500 nm)
Table 1 Size distribution of vesicles secreted from human myotubes
Preparation Filter Vesicles
counted
Mean
diameter (nm)
Standard
deviation (nm)
1 No 119 178.6 56.7
2 No 206 211.8 60.4
3 Yes 154 147.9 54.8
4 Yes 185 154.2 54.9
Vesicles were released from human myotubes by ionomycin treat-
ment (1 lM, 10 min), separated by differential centrifugation and
analyzed by electron microscopy. Size distribution did not differ with
or without ﬁltration through a 0.22 lm ﬁlter
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123muscle ﬁber may contribute to impaired muscle function in
LGMD patients.
An interesting question arising from the present study is
the localization of ahnak1 in other muscular dystrophies.
We studied patients with Becker muscular dystrophy but
our material was limited to two muscle biopsy specimens.
Our preliminary data reveal aberrant ahnak1 localization in
the endomysium in these two patients. This may indicate
that extracellular ahnak1 might be a more general phe-
nomenon in muscular dystrophies and is a subject of our
ongoing research.
Another important ﬁnding of our study is the identiﬁ-
cation of ahnak1 in small vesicles (*150 nm) secreted
from myotubes after treatment with ionomycin to induce
Ca
2? rise. This resembles the process of Ca
2? induced
release of enlargeosomes which are non-secretory, cyto-
plasmic organelles competent for regulated exocytosis.
Enlargeosomes participate in plasma membrane enlarge-
ment and repair and contain ahnak1 and annexin 2 as
marker proteins (Borgonovo et al. 2002). Ahnak1-rich
membranes derived from enlargeosome exocytosis undergo
either endocytosis or release in shedding vesicles (Cocucci
et al. 2007, 2009; Lorusso et al. 2006). In general, vesicle
release into the extracellular environment represents a way
for discarding proteins and membrane but also for inter-
cellular communication through the transfer of proteins,
RNA, and miRNA (Cocucci et al. 2009). Shedded vesicles
can also serve as diagnostic markers. Very recently, ah-
nak1-containing vesicles have been detected in the sera of
patients with pancreatic cancer (Uozumi et al. 2010). To
our knowledge here we demonstrate for the ﬁrst time the
release of ahnak1-containing vesicles from differentiated
human myotubes. Thus, endomysial ahnak1 may originate
from skeletal muscle cells in muscular dystrophies fol-
lowing repeated cycles of degeneration and regeneration.
However, other sources of endomysial ahnak1 remain to be
investigated. We can not exclude that it originates from
other cell types like ﬁbroblasts, immune, endothelial, or
smooth muscle cells or could simply represent cellular
remnants.
In summary, the pivotal ﬁnding in our study is the
identiﬁcation of ahnak1 as novel constituent of endomysial
connective tissue in patients with calpainopathy
(LGMD2A) and dysferlinopathy (LGMD2B), two geneti-
cally distinct muscular dystrophies. We demonstrate for the
ﬁrst time the release of ahnak1-containing vesicles from
myotubes that may be one mechanism underlying ahnak1
mislocalization. The perspectives of our study lie in
unravelling the mechanisms of ahnak1 displacement and its
contribution to impaired muscle function.
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